Clinical Characteristics and Satisfaction of Liraglutide Treatment among Patients with Type 2 Diabetes: A Prospective Study

Ayman A Al Hayek, Asirvatham A Robert and Mohamed A Al Dawish

Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

ABSTRACT:

BACKGROUND: Evaluation of patient-reported results, treatment satisfaction, in particular, is popularly gaining recognition as crucial to the assessment of the efficiency of new therapies. The aim of this study is to examine the clinical features and treatment satisfaction with liraglutide in insulin-dependent obese patients having uncontrolled diabetes.

METHODS: A prospective study was performed for 12 weeks using 64 type 2 diabetes (T2D) patients, 30 to 70 years of age, who came in for treatment to the Diabetes Treatment Center in Prince Sultan Military Medical City, Riyadh, Saudi Arabia, from November 2017 to July 2018. All the patients enrolled in this study were given liraglutide in addition to their existing treatment. For the first week, they were subcutaneously administered 0.6 mg once per day, which was gradually raised to 1.2 mg after 1 week, and the final given dose went up to 1.8 mg per day until the study period was completed. Purposive and suitable selection of the respondents was performed at their convenience. They were interviewed adopting the Diabetes Treatment Satisfaction Questionnaire (Arabic version) at baseline and after 12 weeks. Besides, the clinical variables like hemoglobin A1c (HbA1c), fasting blood sugar (FBS), total daily insulin dose (TDD), number of injections, and hypoglycemia/weeks were also recorded at baseline and at the end of the study.

RESULTS: In comparison with the baseline values, notable positive differences were identified in the domains of treatment satisfaction, namely, satisfied with current treatment ($P = .0001$), frequency of perceived hyperglycemia ($P = .0001$), frequency of perceived hypoglycemia ($P = .0001$), convenience of current treatment ($P = .0001$), understanding diabetes ($P = .0001$), recommend the current treatment ($P = .018$), and continue the present treatment ($P = .0001$) when the study is completed. After 12 weeks, the addition of liraglutide to the existing treatment showed significant positive changes on FBS ($P = .0001$), HbA1c ($P = .001$), TDD ($P = .0001$), number of injections ($P = .0001$), documented hypoglycemia/weeks ($P = .0005$), and body weight ($P = .0001$) in comparison with the baseline values.

CONCLUSIONS: The addition of liraglutide to the existing treatment raised the level of treatment satisfaction and minimized the frequency of hypoglycemic/hyperglycemic events apart from the other clinical variables.

KEYWORDS: diabetes treatment, type 2 diabetes, treatment satisfaction, liraglutide

Introduction

The most recent reports from World Health Organization (WHO) and from the International Diabetes Federation (IDF) revealed that over the past 30 years there has been a dramatic increase in the prevalence of type 2 diabetes (T2D) worldwide.1,2 Furthermore, an estimate indicated that diabetes directly accounted for nearly 1.6 million deaths. In fact, the WHO predicts that diabetes will rank seventh as the cause of death by 2030.1

Diabetes is a disease that is eminently treatable, and its repercussions too can be easily prevented or blocked by incorporating amendments in the diet, physical activity, and medication, and obtaining regular screening and treatment for the T2D-related complications.3–6 Several medications are available for diabetes which can pose difficulties for the selection of the ones more suited for specific patients. Evaluation of patient-reported results, treatment satisfaction, in particular, is popularly gaining recognition as crucial to the assessment of the efficiency of new therapies.7,8 Treatment compliance, glycemic control, and treatment preference are all found to be related to treatment satisfaction.8

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or incretin mimetics are injectable hormones that raise the glucose-dependent insulin secretion and lower the glucagon secretion by inciting the beta cells.9,10 One of the approved GLP-1 RAs to treat diabetes is liraglutide (Victoza).11 Besides, from prior studies, it is evident that Victoza (liraglutide) 1.2 mg or 1.8 mg is an injectable prescription medication for T2D adults which together with diet and exercise may raise the blood glucose and glycated hemoglobin levels with low risk for hypoglycemia, hyperglycemia, and weight loss.12–14 From the research, it is clear that, when insulin therapy is started, patients initially undergo some degree of diabetes-related distress, meaning that they may consider the injection regimen as highly...
demanding, and more often than not they feel quite unsatisfied with their diabetes treatment than do their normal counterparts. In fact, patient satisfaction has become an acceptable indicator of health care quality, very significant in chronic diseases such as T2D.

Much research has been performed on the factors linked to diabetes treatment satisfaction. Patients with T2D showing higher levels of glycosylated hemoglobin (HbA1c) and increased weight expressed a lower degree of satisfaction, as did patients with diabetes-related complications. However, only limited studies are available for the use of liraglutide and treatment satisfaction among the patients on insulin therapy. Therefore, this study aimed at identifying the clinical features and treatment satisfaction in obese insulin-dependent patients with uncontrolled diabetes, after adding liraglutide along with the existing treatment.

**Methods**

*Study design and setting*

A 12-week prospective study was performed using 71 T2D patients who visited the Diabetes Clinic at Diabetes Treatment Center, Prince Sultan Military Medical City (PSMMC), Saudi Arabia from November 2017 to July 2018, adopting the protocol drawn up by the Declaration of Helsinki and approved by the PSMMC Research Ethics Committee. Out of 71 patients, 7 did not continue the study for reasons that violated the inclusion criteria, failed to tolerate, not willing to continue the medication, or for personal reasons. It should be mentioned here that those who failed to show up at 12 weeks after the baseline visit were also completely excluded from the study. A total of 64 patients continued until the end of the study.

*Inclusion and exclusion criteria*

The study involved 30- to 70-year-old obese patients (body mass index [BMI] ≥ 30 kg/m²) with uncontrolled T2D (HbA1c > 7%), undergoing insulin treatment and naïve to liraglutide therapy and being followed up for a minimum of 1 year. Patients who were excluded were those with a history of psychopathology, pregnant or intending to become pregnant, breast-feeding, as well as those having a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or hematological system, medical instability, and impairments of the visual, hearing, or cognitive aspects.

*Patient selection criteria and treatment*

For this study, each patient was carefully selected keeping in mind their convenience and availability during their scheduled routine outpatient clinic visits. Informed consent for participation in the study, both verbal and written, was obtained from the patients regarding aim and methodology prior to completion of the study. Participants were free to opt out of the research at will, and no explanations were required. In this study, all the patients included were administered liraglutide subcutaneously, with an initial dosage of 0.6 mg once per day for the first week and then increased after 1 week to 1.2 mg and the dose given being raised to 1.8 mg per day until the study completion. Those who failed to tolerate the 1.2 mg/1.8 mg dose were excluded from the study, whereas those intolerant to the 1.8 mg dose were advised to continue with the 1.2 mg dose per day (Figure 1).

*Data collection*

The standardized questionnaire was used and patient age, weight, height, and length in time of diabetes were recorded. Clinical variables such as HbA1c and diabetes treatment satisfaction were collected at baseline and at the 12th week. Hypoglycemia: All the patients in the study were requested to record finger stick blood glucose readings in a standard self-monitoring blood glucose diary that was reviewed and documented to identify any hypoglycemic or hyperglycemic events. The hypoglycemic events were defined to standardized concepts: an event indicated a measured glucose concentration of ≤70 mg/dL (documented hypoglycemia).

*Diabetes treatment satisfaction*

The Diabetes Treatment Satisfaction Questionnaire (DTSQ) was developed to determine the degree of patient satisfaction with the treatment offered. Being translated and used widely in several countries, DTSQ is now extensively used in more than 100 languages, because it is quite easy to answer and usable for both patients undergoing medical therapy as well as those lacking it. The DTSQ is internationally validated and officially
approved by WHO and the IDF for both type 1 and type 2 diabetes (T2D). This study used a specifically designed and validated Arabic version of the DTSQ to measure satisfaction with the diabetes treatment. The goal of this tool is to estimate the changes in the level of patient satisfaction regarding therapy modifications, as well as to compare the degree of satisfaction among those employing different treatment strategies. The DTSQ provides a high degree of accuracy in measuring treatment satisfaction in T2D patients. The DTSQ includes 8 health concepts: 6 questions deal with general satisfaction with scores from 0 (very dissatisfied) to 6 (very satisfied). Scores were calculated as the total of 6 satisfaction items: “current treatment,” “convenience,” “flexibility,” “understanding,” “recommend,” and “continue,” yielding a total score between 0 and 36. The other 2 items, namely, events of “perceived frequency of hyperglycemia” and “perceived frequency of hypoglycemia,” were independently estimated. Both questions were calculated with a score from 0 (never experienced) to 6 (most of the time).

Statistical analysis

Data analysis was performed employing the Microsoft Excel 2010 (Microsoft Corporation, Seattle, WA, USA) and Statistical Package for Social Sciences version 22.0 (SPSS Inc, Chicago, IL, USA). Apart from the descriptive analysis, the differences present in the group were identified using the paired “t” test. Pearson’s correlation coefficient was used to find the statistical association between treatment satisfaction score and clinical parameters. Data are expressed as mean ± standard deviation. A P value of <.05 was accepted as statistically significant.

Results

The traits of the study population and treatment procedure are shown in Table 1 and Figure 1. Most of the patient population in the study falls within the 30- to 50-year age group (58%), are female (53.1%), and have had diabetes for >7 years (60.9%).

In Table 2, the differences in the treatment satisfaction assessments performed at baseline and after 12 weeks of the study are evident in the following categories: satisfied with current treatment, frequency of hyperglycemia, frequency of hypoglycemia, convenience, flexibility, understanding, and recommend current treatment. When compared with the baseline level, significant positive differences are distinct in the categories: (1) satisfied with current treatment (P=.0001), (2) frequency of hyperglycemia (P=.0001), (3) frequency of hypoglycemia (P=.0001), (4) convenience of current treatment (P=.0001), (5) understanding diabetes (P=.0001), (6) recommend the current treatment (P=.018), and (7) continue the current treatment (P=.0001) after the study completion. Compared with baseline (14.5 ± 2.4), a significant improvement was found in the overall diabetes treatment satisfaction at the end of the study (19.6 ± 3.6; P=.0001).

From Table 3, the differences in clinical characteristics with current treatment on fasting blood sugar (FBS), HbA1c, total daily insulin dose (TDD), number of injections, and documented hypoglycemia/weeks are clearly seen in the study population at baseline and after 12 weeks of the study. When compared with the baseline level, significant positive differences are evident in the domains: satisfied with FBS (P=.0001), TDD (P=.0001), number of injections (P=.0001), and hypoglycemia/weeks (P=.0005).

From Figures 2 and 3, a notable difference was observed in the study population regarding perceived hyperglycemia, hypoglycemia, HbA1c, and body weight. The liraglutide treatment showed improvements in perceived hyperglycemia (P=.0001) and hypoglycemia (P=.0001). Furthermore, body weight (P=.0001) and HbA1c (P=.0001) of the study population also showed a remarkable decrease.
Table 2. Effectiveness of liraglutide on DTSQ scores.

| DIABETES TREATMENT SATISFACTION                  | BASELINE (MEAN ± SD) | 12 WEEKS (MEAN ± SD) | CHANGES | PAIRED "T" TEST | P VALUE |
|-------------------------------------------------|---------------------|---------------------|---------|----------------|---------|
| Satisfied with current treatment                 | 2.11 ± 1.2          | 3.61 ± 0.6          | 1.5     | −8.7           | .0001   |
| Convenience of current treatment                 | 2.11 ± 1.4          | 2.94 ± 0.8          | 0.83    | −3.8           | .0001   |
| Flexibility of current treatment                 | 2.31 ± 1.4          | 2.70 ± 1.0          | 0.39    | −1.6           | .108    |
| Understanding diabetes                            | 2.20 ± 1.6          | 3.16 ± 0.8          | 0.96    | −4.0           | .0001   |
| Recommend the current treatment                  | 2.73 ± 1.3          | 3.42 ± 1.4          | 0.69    | −2.4           | .018    |
| Continue the present treatment                   | 2.67 ± 1.6          | 3.80 ± 1.0          | 1.13    | −4.2           | .0001   |
| Total satisfaction score (Q 1, 4, 5, 6, 7, 8)    | 14.5 ± 2.4          | 19.6 ± 3.6          | 5.10    | −9.7           | .0001   |

DTSQ, Diabetes Treatment Satisfaction Questionnaire.
Baseline versus 12 weeks compared by paired t test; data are expressed as mean ± standard deviation.

Table 3. Effectiveness of liraglutide on clinical outcomes.

| CLINICAL VARIABLES                  | BASELINE (MEAN ± SD) | 12 WEEKS (MEAN ± SD) | CHANGES | PAIRED "T" TEST | P VALUE |
|-------------------------------------|---------------------|---------------------|---------|----------------|---------|
| Fasting blood sugar (mg/dL)         | 182 ± 20.8          | 160 ± 27.8          | 22      | 5.5            | .0001   |
| Total daily insulin dose (U/kg/day) | 1.1 ± 0.04          | 0.66 ± 0.47         | 0.44    | 5.7            | .0001   |
| Number of injections/day             | 2.56 ± 0.83         | 1.47 ± 0.50         | 1.0     | 9.0            | .0001   |
| Documented hypoglycemia/week        | 2.22 ± 0.8          | 1.92 ± 0.94         | 29      | 2.9            | .0005   |

Baseline versus 12 weeks compared by paired t test; data are expressed as mean ± standard deviation.

Figure 2. Effectiveness of liraglutide treatment on perceived hyperglycemia (A) and hypoglycemia (B) (DTSQ scores; Q 2, 3).

Baseline versus 12 weeks compared by paired t test; data are expressed as mean ± standard deviation.

Figure 3. Effectiveness of liraglutide treatment on body weight (A) and hemoglobin A1C (B).

Baseline versus 12 weeks compared by paired t test; data are expressed as mean ± standard deviation.
Significantly, in this study, we also identified that the subdomains of frequency of hyperglycemia ($P=0.001$) and frequency of hypoglycemia ($P=0.001$) were definitely fewer in frequency from the baseline compared with the final point of assessment. Hypoglycemia and hyperglycemia have been well recognized simply as infrequent adverse effects in T2D patients on hypoglycemic agents and are related to reduced health-related QoL and treatment satisfaction. Some recent studies further reported that patients with moderate or severe hypoglycemic symptoms showed lower satisfaction levels with their treatment and reduced commitment to medication than those lacking or having the symptoms. It is noteworthy that the current treatment algorithm in this study was not related to any severe adverse events, neither to severe hypoglycemia nor to hyperglycemia; overall, during the trial the number of events of non-severe hypoglycemia and hyperglycemia was low, and higher satisfaction scores were reported among those in this study population.

With respect to the clinical variables, this study observed that the addition of liraglutide to the existing treatment produced positive differences in the FBS ($P=0.001$), HbA$_{1c}$ ($P=0.001$), TDD ($P=0.001$), number of injections ($P=0.001$), and documented hypoglycemia/week ($P=0.005$). Several studies indicate that liraglutide is a GLP-1 RA because the GLP-1 RAs encourage insulin secretion according to the blood glucose levels, by reducing the hypoglycemic episodes, glycemic control, fasting plasma glucose, and total insulin need. Concurring with our results, earlier research also showed that liraglutide lowers the FBS and glycated hemoglobin, with a low risk of hypoglycemia. From the recent studies, liraglutide was noted to appreciably heighten the glycemic control and lower the body weight without adversely affecting the QoL in T2D patients with obesity.

Among the comorbid conditions in most T2D patients, obesity ranks high and the increase in the basal insulin

Table 4. Age and sex differences in diabetes treatment satisfaction scores and hemoglobin $A_{1c}$.

| DIABETES TREATMENT SATISFACTION AND HEMOGLOBIN A$_{1c}$ | SEX (MEAN±SD) | $P$ VALUE | AGE (MEAN±SD) | $P$ VALUE |
|---------------------------------------------------------|---------------|------------|---------------|------------|
|                                                          | FEMALE        | MALE       | 30-50 YEARS   | 51-70 YEARS|
| Satisfied with current treatment                         | 3.8±0.71      | 3.4±1.5    | .25           | 3.76±1.18  | 3.41±1.3  | .27 |
| Perceived hyperglycemia                                 | 2.17±0.59     | 2.09±0.66  | .62           | 2.22±0.63  | 2.0±0.62  | .17 |
| Perceived hypoglycemia                                  | 2.13±1.04     | 1.68±0.76  | .04           | 1.97±0.83  | 1.78±1.05 | .41 |
| Convenience of current treatment                         | 2.7±1.36      | 3.15±1.52  | .22           | 2.78±1.47  | 3.15±1.43 | .32 |
| Flexibility of current treatment                         | 2.4±1.32      | 2.97±1.6   | .12           | 2.46±1.4   | 3.04±1.58 | .12 |
| Understanding diabetes                                   | 3.17±1.72     | 3.15±1.61  | .96           | 3.08±1.7   | 3.26±1.6  | .67 |
| Recommend the current treatment                          | 3.83±1.57     | 3.06±1.62  | .06           | 3.35±1.68  | 3.52±1.60 | .69 |
| Continue the present treatment                           | 3.93±1.63     | 3.68±1.64  | .53           | 4.03±1.59  | 3.48±1.67 | .19 |
| Total satisfaction score                                 | 19.8±1.63     | 19.4±4.1   | .66           | 19.4±3.7   | 19.8±3.4  | .67 |
| Hemoglobin $A_{1c}$                                     | 8.0±0.21      | 8.03±0.38  | .68           | 8.0±0.12   | 8.04±0.43 | .60 |

Baseline versus 12 weeks compared by paired $t$ test; data are expressed as mean±standard deviation.
treatment has been found to be linked to further weight gain and heightened risk of hypoglycemia. In fact, multiple insulin injections administered daily normally induce even greater weight gain. Therefore, several individuals on multiple daily insulin injections end up having even higher insulin resistance and obesity, and frequently fail to achieve adequate glycemic control.21,29,36,37 From the findings of recent studies, liraglutide was observed to clearly improve glycemic control and decrease body weight in obese patients.23,29,36,37 The findings from this study also showed beyond doubt that the additional 12-week treatment of liraglutide plus the existing treatment caused a greater loss in body weight in the population under study. In a recent study, the weight loss and improved glycemic control induced by the added liraglutide were both linked to high levels of patient satisfaction.36

This study was mainly limited by the relatively small sample size, short-term duration, and the fact that the study was performed at only 1 center. Furthermore, the absence of a control group against which the study group could be compared limited the results, to the extent that they cannot be generalizable to real-world situations. Therefore, more research works, larger in scale and over longer time periods, are required to overcome these limitations. In conclusion, the addition of liraglutide to the existing treatment was proven to be an effective option for obese T2D patients, as it facilitated a decrease in body weight, better glycemic control, and lower frequency of hypoglycemia/hyperglycemia apart from the clinical variables. The liraglutide treatment also boosted the treatment satisfaction levels among the obese patients with T2D.

Author Contributions
AAAH and MAAD conceived and designed the study and contributed to the writing of the manuscript. AAAH and AAR wrote the first draft of the manuscript and agreed with manuscript results and conclusions. MAAD made critical revisions and approved the final version of the manuscript. All authors reviewed and approved the final manuscript.

Data Sharing Statement
There is no data sharing as this manuscript and the data were not published elsewhere.

Ethical Approval
The study protocol was approved by the Research and Ethics committee of Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Informed Consent
During the informed consent process, the study participants were assured that the data collected will be used only for stated purposes and will not be disclosed or released to others without the consent of the participants.

REFERENCES
1. International Diabetes Federation (IDF). IDF Diabetes Atlas. 8th ed. Brussels, Belgium: IDF; 2017. http://www.diabetesatlas.org.
2. Alotaibi A, Perry L, Gholidadeh L, Al-Gammi A. Incidence and prevalence rates of diabetes mellitus in Saudi Arabia: an overview. J Epidemiol Glob Health. 2017;7:211–218.
3. Asif M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. J Educ Health Promot. 2014;3:1.
4. Guo J, Tang Y, Wiley J, Whitemore R, Chen JL. Effectiveness of a diabetes prevention program for rural women with prior gestational diabetes mellitus: study protocol of a multi-site randomized clinical trial. BMC Public Health. 2018;18:809.
5. Ibrahim M, Tuomilehto J, Aschner P, et al. Global status of diabetes prevention and prospects for action: a consensus statement. Diabetes Metab Res Rev. 2018;34:e3201.
6. Dugan J, Cantillep A, Newberry K, Shrubrook J. A call to action on prediabetes. JAMA. 2018;319:26–30.
7. Marra G, DIAB & TER.S Project Study Group. The DIAB & project: how patients perceive diabetes and diabetes therapy. Acta Biomed. 2004;75:164–170.
8. Peyrot M, Rubin RR. How does treatment satisfaction work? modeling determinants of treatment satisfaction and preference. Diabetes Care. 2009;32:111–114.
9. Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism. 2014;63:9–19.
10. Dahlyquist S, Ahlen E, Fipipson K, et al. Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in patients with type 2 diabetes (MDI Liraglutide trial 3). BMJ Open Diabetes Res Care. 2016;6:e000464.
11. Lorenz M, Evers A, Wagner M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabetes. Bioorg Med Chem Lett. 2015;23:4011–4018.
12. Hunter B, Vega-Hernandez G, Valentine WJ, Kraag N. Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Diabetes Obes Metab. 2017;19:842–849.
13. Lundershausen R, Muller S, Hashim M, Kienhofer J, Kipper S, Wilke T. Quality of life, glycemic control, safety and tolerability associated with liraglutide or insulin initiation in patients with type 2 diabetes in Germany: results from the prospective, non-interventional LIBERTY study [published online ahead of print August 29, 2018]. Exp Clin Endocrinol Diabetes. doi:10.1055/a-0636-3961.
14. Costa GilJE, Faingold MC, Fuente GV, Litwak LE, Rodriguez M. Efficacy and safety of Liraglutide for the intensification of type 2 diabetes treatment. Medicina. 2018;78:225–233.
15. Phillipov G, Phillips PJ. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2006;29:952–953.
16. Takase T, Nakamura A. Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: a randomized controlled trial [published online ahead of print August 4, 2018]. J Diabetes Investig. doi:10.1111/jdi.12906.
17. Boels AM, Vos RC, Hermans TGT, et al. What determines treatment satisfaction of patients with type 2 diabetes on insulin therapy? an observational study in eight European countries. BMJ Open. 2017;7:e016180.
18. Iqbal Z, Azmi S, Yadav R, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther. 2018;40:828–849.
19. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37:S14–S80.
20. Saisho Y. Use of Diabetes Treatment Satisfaction Questionnaire in diabetes care: importance of patient-reported outcomes. Int J Environ Res Public Health. 2018;15:915.E947. doi:10.3390/ijerph15050947.
21. Yamamoto S,Hayashi T,Ohara M,et al.Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: a randomized prospective pilot study. Diabetes Res Clin Pract. 2018;140:339–346.
22. Wilbur K. Diabetes Treatment Satisfaction Questionnaire—an Arabic adaptation for Qatar. Diabetes Res Clin Pract. 2013;99:e24–e26.
23. Kalra S, Barhanu MP, Sahay RK, Unnikrishnan AG, Uppal S, Adeduwi O. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future. Indian J Endocrinol Metab. 2016;20:254–267.
24. Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R. Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diab Metab. 2011;28:333–337.
25. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25:245–254.
26. Rubin RR, Peyrot M. Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for AIC Reduction 3 (STAR 3) trial. Diabetes Technol Ther. 2012;14:143–151.
27. Alazri MH, Neal RD. The association between satisfaction with services provided in primary care and outcomes in type 2 diabetes mellitus. *Diabet Med*. 2003;20:486–490.

28. Wals L, Pettersson B, Rosenqvist U, Deleskog A, Journath G, Wandell P. Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetes. *Patient Prefer Adherence*. 2014;8:593–601.

29. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. *Ther Adv Endocrinol Metab*. 2015;6:19–28.

30. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. *Diabetes Res Clin Pract*. 2008;81:161–168.

31. Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. *Adv Ther*. 2011;28:213–226.

32. Mori Y, Taniguchi Y, Sezaki K, Yokoyama J, Utsunomiya K. Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study. *Diabetes Technol Ther*. 2011;13:1139–1144.

33. Lind M, Hirsch IB, Tuomilehto J, et al. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). *BMJ*. 2015;351:h5384.

34. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *Lancet*. 2010;375:1447–1456.

35. Wagner AM, Miranda-Calderin G, Ugarte-Lopetegui MA, et al. Effect of liraglutide on physical performance in type 2 diabetes: results of a randomized, double-blind, controlled trial (LIPER2) [published online ahead of print September 14, 2018]. *Diabetes Metab*. doi:10.1016/j.diabet.2018.08.010.

36. Ishii H, Niya T, Ono Y, Inaba N, Jinnouchi H, Watada H. Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study. *Diabetes Metab Syndr*. 2017;9:3. doi:10.1016/j.dsx.2016.07.016.

37. Pokala N, Adams-Huet B, Li X, Harrison LB, Vanderheiden A, Lingvay I. The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin. *Diabetes Obes Metab*. 2017;19:1454–1457.